Viewing data from:

KEPPRA

NDA

LEVETIRACETAM | N021035 | UCB INC

4 strengths1 unique patent0 unique exclusivities

Patent Timeline

1 unique patent by expiration date

Active (1)TodayPED (+6 mo)

2027

2028

2029

2030

2031

2032

Today

8802142

Dec. 7, 2031

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.

Citizen Petitions

3 petitions (2 open) from Regulations.gov

Petition	Type	Filed	Status	Petitioner
Suitability Petition from Lachman Consulting Services, Inc. FDA-2026-P-5876 · 6 docket documents Lachman Consulting Services, Inc. filed a suitability petition requesting that the FDA determine whether certain inactive ingredients, manufacturing processes, or other pharmaceutical components meet established regulatory standards for use in drug products. The petition seeks FDA guidance on whethe	Suitability	2026-05-21	Open	Lachman Consulting Services, Inc.
Nexus Pharmaceuticals, Inc. - Citizen Petition FDA-2011-P-0186 · 5 docket documents Nexus Pharmaceuticals, Inc. filed this suitability petition requesting that the FDA declare Levetiracetam Injection 1000 mg/Vial suitable for submission as an Abbreviated New Drug Application under section 505(j)(2)(c) of the Federal Food, Drug, and Cosmetic Act, with the reference listed drug being	Other	2011-04-04	Open	—
The Weinberg Group, Inc. - Citizen Petition FDA-2009-P-0285 · 5 docket documents The Weinberg Group Inc. filed a suitability petition on June 19, 2009, requesting that the FDA declare Levetiracetam Extended-Release Tablets in 1000 mg and 1500 mg strengths suitable for submission as an ANDA, with the reference listed drug being Keppra XR 750 mg approved under NDA 22-285, arguing	Other	2009-06-23	GrantedUnverified summary	—

Source: Regulations.gov. FDA citizen petitions matched by application number.

Clinical Trials

189 trials from ClinicalTrials.gov — 6 recruiting, 1 active, 143 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults NCT06919926	Phase 2	Active	Johns Hopkins University	60	2025-04-17 → 2028-05
Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma NCT07758062	Phase 2	Not Yet Recruiting	Tianjin Medical University General Hospital	140	2026-09-01 → 2029-09-01
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly NCT06345495	Phase 2	Recruiting	M.D. Anderson Cancer Center	30	2024-10-01 → 2029-01-01
Seizure Treatment in Glioma NCT03048084	Phase 4	Recruiting	Leiden University Medical Center	120	2018-02-01 → 2029-07-01
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)NCT01666080	N/A	Recruiting	Masonic Cancer Center, University of Minnesota	30	2012-08 → 2028-06
Levetiracetam for Persons at Risk for Alzheimer's Disease NCT07477431	Phase 2	Recruiting	Sunnybrook Health Sciences Centre	40	2025-10-23 → 2028-02
Investigating the Effect of a Single-dose of Levetiracetam on Brain Function, Chemistry and Cognitive Performance in Psychosis Risk NCT06224530	N/A	Recruiting	King's College London	69	2024-07-19 → 2026-08-30
Levetiracetam in Chronic Neuropathic Pain Following Spinal Cord Injury NCT00252954	Phase 4	Completed	Danish Pain Research Center	36	2005-11 → 2008-12
Efficacy of Intravenous Levetiracetam in Neonatal Seizures NCT01720667	Phase 1/2	Completed	Richard H. Haas	280	2013-03 → 2019-07-31
Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy NCT00150748	Phase 3	Completed	UCB Pharma SA	217	2001-11 → 2007-07

Source: ClinicalTrials.gov. Trials matched by ingredient name; data refreshed each weekday and may lag the registry.

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-08-26 | 4 NDCs

Highest NADAC/Unit

$19.88

per ea

Lowest NADAC/Unit

$8.08

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
50474059766KEPPRA 1,000 MG TABLET	$19.88	EA	Brand	$0.1566	2026-08-19
50474059640KEPPRA 750 MG TABLET	$13.46	EA	Brand	$0.1105	2026-08-19
50474059540KEPPRA 500 MG TABLET	$9.92	EA	Brand	$0.0739	2026-08-19
50474059440KEPPRA 250 MG TABLET	$8.08	EA	Brand	$0.0584	2026-08-19

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 8 NDCs (4 FSS, 4 Big4)

Lowest Price

$726.85

Highest Price

$1384.01

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
50474-0594-40KEPPRA 250MG TAB	$726.85	Big4	UCB, Inc.	09/14/2030
50474-0594-40KEPPRA 250MG TAB	$835.82	FSS	UCB, Inc.	09/14/2030
50474-0595-40KEPPRA 500MG TAB	$863.83	Big4	UCB, Inc.	09/14/2030
50474-0595-40KEPPRA 500MG TAB	$1021.56	FSS	UCB, Inc.	09/14/2030
50474-0596-40KEPPRA 750MG TAB	$1166.79	Big4	UCB, Inc.	09/14/2030
50474-0596-40KEPPRA 750MG TAB	$1384.01	FSS	UCB, Inc.	09/14/2030
50474-0597-66KEPPRA 1000MG TAB	$840.19	Big4	UCB, Inc.	09/14/2030
50474-0597-66KEPPRA 1000MG TAB	$1021.56	FSS	UCB, Inc.	09/14/2030

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Keppra (2024)

Total Spending

$71.7M

Total Claims

37,683

Beneficiaries

5,281

Avg Cost/Unit

$12.26

Spending Trend

$77.7M(2019)→$77.8M(2020)→$75.2M(2021)→$76.7M(2022)→$76.3M(2023)→$71.7M(2024)

YoY Change:-1.9%

5yr CAGR:+4.3%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

Medicare Part B Spending

CMS physician-administered drug spending for Keppra (2024)

Total Spending

$3K

Total Claims

324

Beneficiaries

135

ASP Price

$0.06

Spending Trend

$7K(2019)→$4K(2020)→$3K(2021)→$3K(2022)→$3K(2023)→$3K(2024)

YoY Change:+18.2%

5yr CAGR:+11.5%

HCPCS: J1953 — Injection, levetiracetam, 10 mg

Source: CMS Medicare Part B Spending by Drug (2024). Shows physician-administered drug costs.

API Supply Chain30 active DMFs18 inactive

26 active API suppliers hold Drug Master Files for this ingredient.

DIVIS LABORATORIES LTDLEVETIRACETAM

DMF 168942003

DR REDDYS LABORATORIES LTDLEVETIRACETAM

DMF 169662003

HETERO LABS LTDLEVETIRACETAM (FORM 1)

DMF 177382004

NEULAND LABORATORIES LTDLEVETIRACETAM USP

DMF 177992004

LUPIN LTDLEVETIRACETAM USP

DMF 190802005

APITORIA PHARMA PRIVATE LTDLEVETIRACETAM USP

DMF 193872006

ORBION PHARMACEUTICALS PRIVATE LTDLEVETIRACETAM

DMF 197472006

SUN PHARMACEUTICAL INDUSTRIES LTDLEVETIRACETAM USP

DMF 214142008

ESTEVE QUIMICA SALEVETIRACETAM INJECTABLE GRADE/NON-STERILE

DMF 218372008

ZHEJIANG HUAHAI PHARMACEUTICAL CO LTDLEVETIRACETAM USP (PROCESS II)

DMF 238532010

JUBILANT PHARMOVA LTDLEVETIRACETAM USP

DMF 242002010

SRINI PHARMACEUTICALS PRIVATE LTDLEVETIRACETAM USP

DMF 247572011

ZHEJIANG APELOA JIAYUAN PHARMACEUTICAL CO LTDLEVETIRACETAM

DMF 250052011

AMOLI ORGANICS PVT LTDLEVETIRACETAM USP [ROUTE CODE - LVS]

DMF 257622012

SOLARA ACTIVE PHARMA SCIENCES LTDLEVETIRACETAM USP

DMF 265002012

SMS PHARMACEUTICALS LTDLEVETIRACETAM USP

DMF 284312014

DIVIS LABORATORIES LTDLEVETIRACETAM (PROCESS B)

DMF 301852016

HETERO LABS LTDLEVETIRACETAM (FORM-1), PROCESS-II

DMF 306262016

MSN LIFE SCIENCES PRIVATE LTDLEVETIRACETAM USP

DMF 336082019

AURORE LIFE SCIENCES PRIVATE LTDLEVETIRACETAM USP

DMF 340972019

INNOVARE LABS PRIVATE LTDLEVETIRACETAM USP

DMF 345932020

AURORE LIFE SCIENCES PRIVATE LTDLEVETIRACETAM FORM-I USP

DMF 352722020

CHIERON ACTIVE INGREDIENTS PRIVATE LTDLEVETIRACETAM

DMF 353162020

EMNAR PHARMA PRIVATE LTDLEVETIRACETAM USP

DMF 354412020

SHAOXING JINGXIN PHARMACEUTICALS CO LTDLEVETIRACETAM

DMF 356292021

IOL CHEMICALS AND PHARMACEUTICALS LTDLEVETIRACETAM USP

DMF 363742021

GRANULES INDIA LTDLEVETIRACETAM USP

DMF 377752022

ZHEJIANG HUAHAI PHARMACEUTICAL CO LTDLEVETIRACETAM, USP (PROCESS VII)

DMF 378522022

VASUDHA PHARMA CHEM LTDLEVETIRACETAM USP

DMF 381302023

RUI LABORATORIES PRIVATE LIMITEDLEVETIRACETAM USP

DMF 412452025

ESTEVE QUIMICA SAInactiveLEVETIRACETAM

DMF 173272004

TEVA PHARMACEUTICAL INDUSTRIES LTDInactiveLEVETIRACETAM

DMF 190332005

RANBAXY LABORATORIES LTDInactiveLEVETIRACETAM

DMF 190512005

HIKAL LTDInactiveLEVETIRACETAM API

DMF 191042006

CAMBREX CHARLES CITY INCInactiveLEVETIRACETAM

DMF 197382006

SIGNA SA DE CVInactiveLEVETIRACETAM USP

DMF 204122007

ALEMBIC PHARMACEUTICALS LTDInactiveLevetiracetam

DMF 211222007

MYLAN LABORATORIES LTDInactiveLEVETIRACETAM USP

DMF 212012007

WANBURY LTDInactiveLEVETIRACETAM

DMF 217432008

ZACH SYSTEM SPAInactiveLEVETIRACETAM

DMF 217472008

ZHEJIANG HUAHAI PHARMACEUTICAL CO LTDInactiveLEVETIRACETAM USP

DMF 222352008

AMOLI ORGANICS PVT LTDInactiveLEVETIRACETAM

DMF 235852010

SECOND PHARMA CO LTDInactiveLEVETIRACETAM

DMF 251202011

WATERSTONE PHARMACEUTICALS (HUBEI) CO LTDInactiveLEVETIRACETAM

DMF 261942012

CTX LIFE SCIENCES PVT LTDInactiveLEVETIRACETAM

DMF 274582013

ZHEJIANG HUAHAI PHARMACEUTICAL CO LTDInactiveLEVETIRACETAM USP (PROCESS V)

DMF 301192015

WANBURY LTDInactiveLEVETIRACETAM

DMF 311492016

ZHEJIANG JIANGBEI PHARMACEUTICAL CO LTDInactiveLEVETIRACETAM

DMF 342222019

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

33 letters from Drugs@FDA

Date	Submission	Document
Mar 13, 2024	SUPPL -115	View Letter (PDF)
Sep 1, 2023	SUPPL -113	View Letter (PDF)
Aug 18, 2023	SUPPL -112	View Letter (PDF)
Oct 1, 2020	SUPPL -104	View Letter (PDF)
Oct 24, 2019	SUPPL -102	View Letter (PDF)
Oct 30, 2017	SUPPL -100	View Letter (PDF)
Apr 27, 2017	SUPPL -99	View Letter (PDF)
Oct 28, 2016	SUPPL -96	View Letter (PDF)
Mar 12, 2015	SUPPL -93	View Letter (PDF)
Aug 11, 2014	SUPPL -94	View Letter (PDF)
Mar 11, 2014	SUPPL -91	View Letter (PDF)
Jul 26, 2013	SUPPL -89	View Letter (PDF)
Dec 21, 2011	SUPPL -74	View Letter (PDF)
Dec 21, 2011	SUPPL -85	View Letter (PDF)
Dec 21, 2011	SUPPL -52	View Letter (PDF)
Dec 21, 2011	SUPPL -73	View Letter (PDF)
Dec 21, 2011	SUPPL -83	View Letter (PDF)
Aug 12, 2011	SUPPL -90	View Letter (PDF)
May 4, 2009	SUPPL -80	View Letter (PDF)
May 4, 2009	SUPPL -78	View Letter (PDF)
Sep 25, 2007	SUPPL -62	View Letter (PDF)
Mar 23, 2007	SUPPL -57	View Letter (PDF)
Aug 18, 2006	SUPPL -50	View Letter (PDF)
Aug 18, 2006	SUPPL -54	View Letter (PDF)
Jan 30, 2006	SUPPL -38	View Letter (PDF)
Jan 20, 2006	SUPPL -48	View Letter (PDF)
Jun 23, 2005	SUPPL -40	View Letter (PDF)
Oct 29, 2004	SUPPL -33	View Letter (PDF)
Oct 29, 2004	SUPPL -32	View Letter (PDF)
Sep 9, 2003	SUPPL -30	View Letter (PDF)
May 22, 2002	SUPPL -19	View Letter (PDF)
May 22, 2002	SUPPL -13	View Letter (PDF)
Nov 30, 1999	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (4)

Sort:

#001 — 250MG

RLDAB

1 patent0 exclusivities▴

TABLET;ORAL | Approved: Nov 30, 1999

Patents (1)

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
8802142	Jun 7, 2031PED: Dec 7, 2031	PED	—	Yes	—	—

#002 — 500MG

RLDAB

1 patent0 exclusivities▾

TABLET;ORAL | Approved: Nov 30, 1999

#003 — 750MG

RLDAB

1 patent0 exclusivities▾

TABLET;ORAL | Approved: Nov 30, 1999

#004 — 1GM

RLDAB

1 patent0 exclusivities▾

TABLET;ORAL | Approved: Jan 6, 2006